UNSPSC 51334411: Nonaperone

This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JLD8OG7GK0. European Medicines Agency schedules Nonaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09349MIG. Nonaperone generally arises in the molecular formula C18H24FNO.

The term NONAPERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) NONAPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nonaperone under HS 29339990 and SITC 51577. As of Q4 2014, NONAPERONE remains the US FDA Preferred Term for this commodity. Nonaperone bears US NLM identifiers UMLS ID C2983883 and NCI Concept Code C90790. SMILES: FC1CCC(C(=O)CCCN2CC3CCC(CC3)C2)CC1.

UNSPSC 51334411 Nonaperone is a Commodity code under which state and local governments procure naloxone, pharmaceutical products, and drug deactivation systems to support public health, addiction-response, and pharmacy benefit programs. The scope spans direct purchase of finished pharmaceutical products (naloxone units, generic multi-source drugs, over-the-counter medications) and associated drug management systems, with procurement crossing health departments, county community health programs, and state Medicaid or pharmacy benefit administrations. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances representing multiple state and local participants. Recent solicitations show Seminole County, Florida seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive IFB; Texas Health and Human Services Commission issuing an RFI to develop a direct-to-manufacturer prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) soliciting multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon.

Activity concentrates in Florida, Texas, and Minnesota in the recent record. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, with response due July 26, 2023, seeks quarterly deliveries with fixed-fee pricing and includes FEMA compliance requirements. The Texas HHS RFI (HHS0017013), posted April 3, 2026, gathers market intelligence on direct manufacturer contracting models and value-based prescription programs before issuing a formal RFP. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026, with response due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026, and requires cGMP and Drug Supply Chain Security Act certification. Vendors must meet insurance, EDI, and compliance requirements; pricing evaluation weights competitiveness at 75 percent and fixed pricing at 10 percent.